Introduction: The purpose of this study was to explore the complicated rearrangement mechanisms underlying cases with atypical and negative anaplastic lymphoma receptor tyrosine kinase gene (ALK) fluorescence hybridization (FISH) and positive immunohistochemistry (IHC) results and to stress the importance of combinational assay of these two methods in current pathological diagnosis.
Methods: A total of 3128 NSCLCs were screened for ALK fusions through both FISH analysis and IHC assays with Ventana-D5F3 antibody. Fourteen cases with atypical and negative FISH results with the current criteria and positive IHC results were analyzed with targeted next-generation sequencing (NGS).
Results: Of the 3128 cases tested, 228 (7.3%) and 214 (6.8%) were ALK positive by IHC and FISH, respectively. Fourteen cases with negative and atypical FISH results all demonstrated IHC positivity. Of 2991 cases, eight (0.27%) with negative FISH results demonstrated echinoderm microtubule associated protein like 4 gene (EML4)-ALK fusions revealed by targeted NGS, and the relative abundance of fusion ranged from 0.9% to 46.8%. Three of 2991 cases (0.1%) did not exhibit any type of ALK fusions. In addition, two patients showed an isolated 5 0 side signal and targeted NGS revealed two novel ALK partner genes, baculoviral IAP repeat containing 6 gene (BIRC6) and phosphatidylinositol binding clathrin assembly protein gene (PICALM). One patient showed an isolated and attenuated 3 0 red signal and demonstrated a novel translocation partner with CCAAT/ enhancer binding protein zeta gene (CEBPZ) . Of all the patients, four received crizotinib treatment and demonstrated partial responses at the end of follow-up.
Conclusions:
Our study showed that patients with negative and atypical ALK FISH patterns may have positive results for IHC testing and harbor the translocation partners of EML4 or other genes. Therefore, additional testing with NGS should be conducted to explore the molecular mechanisms underlying the complicated gene rearrangement events.
Introduction
Detection of anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements in patients with NSCLC has recently become a routine pathological diagnosis worldwide. The significance of ALK examination is supported by the availability of several highly efficient therapeutic anaplastic lymphoma kinase (ALK) inhibitors that almost always provide remarkable benefit to the patients. 1, 2 There are three major conventional diagnostics for ALK fusions: fluorescence in situ hybridization (FISH), real-time reverse-transcriptase polymerase chain reaction (RT-PCR), and immunohistochemistry (IHC). 3, 4 The principle of IHC is based on the fact that activating ALK rearrangements are accompanied by significant overexpression of the catalytic portion of its tyrosine kinase. Our study and others indicate that IHC with Ventana D5F3 antibody (Ventana Medical Systems, Tucson, AZ) is sensitive and specific for determination of ALK status and is a viable alternative to ALK FISH. [5] [6] [7] Although FISH was the first U.S. Food and Drug Administration-approved method to detect fusion genes, some researchers have reported that patients with tumors that were ALK FISH-negative but IHC positive may show a dramatic response after receiving crizotinib treatment. [8] [9] [10] [11] This discordance of FISH and IHC results could possibly be attributed to the existence of multiple translocation partners and complicated rearrangement mechanisms in ALK fusion. Besides the canonical inv(2)(p21p23) rearrangement pattern, there were some rare events for ALK fusion formation, such as random reconnection of echinoderm microtubule associated protein like 4 gene (EML4)-ALK caused by chromothripsis 12 and a large deletion between EML4 and ALK in the genomic level. 10 These rare genomic events led to an ALK FISH-negative and IHC-positive phenotype, and ALK inhibitors showed clinical improvement in these cases. In addition to EML4, other fusion partner genes, such as baculoviral IAP repeat containing 6 gene (BIRC6), 11 TRK-fused gene (TFG), 13 kinesin family member 5B gene (KIF5B), 14 SEC31 homolog A, COPII coat complex component gene (SEC31A), 15 Huntington interacting protein 1 gene (HIP1), 16, 17 translocated promoter region, nuclear basket protein gene (TPR), 18 kinesin light chain 1 gene (KLC1), 19 and dynactin subunit 1 gene (DCTN1), 20 have also been identified as oncogenic events, and these cases often showed the atypical FISH patterns with IHC positivity. Therefore, when negative and atypical FISH patterns are accompanied by positivity in IHC testing, it should be noted that corroborative testing with next-generation sequencing (NGS) should be implemented to further confirm the existence of ALK fusion genes.
Here, we reported a large cohort of cases screened for ALK fusions through both FISH analysis and IHC assays with Ventana-D5F3 antibody. Among them, 14 cases with negative and atypical FISH and positive IHC results were analyzed with targeted NGS. We discovered EML4-ALK fusions with rare genomic events and three novel ALK fusion genes in the discordant cases, and some of these patients showed clinical improvement with crizotinib treatment. Therefore, combinational assay of FISH and IHC for detecting the ALK fusion should be implemented in the routine pathological diagnosis and it is reasonable that collaborative testing with NGS or RT-PCR be conducted in discordant cases to avoid missing cases that could benefit from ALK inhibitors.
Materials and Methods

Patients and Samples
From March 2013 to Jan 2016, a total of 3128 patients were enrolled in this study. Eligible patients were required to have pathologically confirmed NSCLC and sufficient tissue samples for comprehensive analysis. All these samples, including surgical and biopsy specimens, were analyzed with ALK FISH and IHC. Cytological samples were tested for ALK fusion only by FISH. Patients receiving neoadjuvant chemotherapy were excluded. Clinical and pathological data prospectively collected for analyses included age at diagnosis, sex, smoking history, histologic type, tumor differentiation, and histologic subtype of adenocarcinoma according to the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society multidisciplinary classification. A subset of patients received crizotinib treatment and had clinical data available on the outcome. Imaging data were independently reviewed by the authors to evaluate patients' responses to treatment according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Progression-free survival (PFS) was calculated from the date of initiation of tyrosine kinase inhibitor treatment to a radiologic or clinical observation of disease progression. The study protocol was approved by the institutional review board of the Cancer Hospital, Chinese Academy of Medical Sciences (Beijing, China). The methods were carried out in accordance with the approved guidelines. Each participant signed an institutional review board-approved informed consent form in accordance with current guidelines.
FISH Hybridization
FISH analysis was carried out as previously described. 5 In brief, FISH analysis was performed using the Vysis LSI ALK Dual color, Break Apart Rearrangement Probe (Abbott/Vysis, Abbott Park, IL). Samples were considered FISH positive if more than 15% of the scored tumor cells had split one or both ALK 5 0 and 3 0 probe signals or had isolated 3 0 signals. Slides were evaluated independently by two experts who were blinded to the patient's history and histologic findings.
IHC
IHC was carried out on a fully automated Ventana Benchmark XT stainer (Ventana Medical Systems) by using the prediluted Ventana anti-ALK (D5F3) rabbit monoclonal primary antibody, together with the Optiview DAB IHC Detection Kit and Optiview Amplification Kit (Ventana Medical Systems). Each sample was also stained with a matched rabbit monoclonal negative control immunoglobulin antibody. A binary scoring system was adopted for evaluating the staining results. Presence of strong granular cytoplasmic staining in tumor cells (any percentage of positive tumor cells) was deemed to indicate ALK positivity, whereas absence of strong granular cytoplasmic staining in tumor cells was deemed to indicate ALK negativity.
Targeted NGS
For 14 patients with atypical negative FISH and positive IHC results, targeted NGS was performed as previously reported. 21 Briefly, genomic DNA was profiled by using a capture-based targeted sequencing panel (Burning Rock Biotech, Guangzhou, People's Republic of China), including all exons in 56 genes and selected introns in ALK, ret proto-oncogene (RET), and ROS1 for the detection of translocation events. The concentration of the DNA samples was measured with the Qubit dsDNA assay (Thermo Fisher Scientific, Waltham, MA). Fragments 200 to 400 base pairs in size were selected with beads (Agencourt AMPure XP kit [Beckman Coulter, Brea, CA]), followed by hybridization with the capture probe baits, hybrid selection with magnetic beads, and PCR amplification. A bioanalyzer high-sensitivity DNA assay was then used to assess the quality and size range. Available indexed samples were then sequenced on a Nextseq sequencer (Illumina, San Diego, CA) with paired-end reads. Sequence data were analyzed by GATK 3.2 22 and DNA translocation analysis was performed by using both Tophat2 23 and Factera 1.4.3. 24 
Statistical Analysis
Differences in patient characteristics and clinicopathologic factors in the two-dimensional crosscomparison were evaluated statistically by Pearson's c 2 test or Fischer's exact test. Statistical tests were two sided, and p less than 0.05 was considered significant. PFS was calculated using the Kaplan-Meier method. Statistics were carried out using SPSS software, version 16.0 (SPSS, Inc., Chicago, IL).
Results
Screening for ALK Fusions through FISH and IHC
Of the 3128 cases tested, 2603 (83.2%), 388 (12.4%), and 137 (4.4%) were tested using surgical, biopsy, and cytological specimens, respectively ( Table 1 ). The overall rates of positivity for ALK IHC D5F3 and FISH were 7.3% (228) and 6.8% (214), respectively. ALK FISH identified 157 of 2603 positive surgical (6.0%), 41 of 388 positive biopsy (10.6%), and 16 of 137 positive cytological specimens (11.7%), respectively. And the ALK IHC D5F3 assay identified 162 of 2603 positive surgical specimens (6.2%) and 50 of 388 positive biopsy specimens (12.9%). Specimens from 2991 cases were tested by both ALK FISH and IHC analysis. Of those 2991 specimens, 11 (0.35%) demonstrated positive IHC results with negative FISH results and three (0.1%) showed atypical FISH patterns with a positive IHC result (Fig. 1 ).
Clinicopathologic Features of Negative and Atypical FISH Cases
The detailed clinicopathologic features of the 14 patients with lung adenocarcinoma with IHC D5F3-positive and FISH-negative results are listed in Table 2 . Of these patients, half were female. The mean age at presentation was 49.4 ± 13.9 years. Five patients were current smokers with an average smoking history of 16.6 pack-years and nine patients were nonsmokers. Four samples were from curative surgical procedures and 10 were biopsy specimens. Seven tumors were of the solid subtype with mucinous differentiation and the others were not evaluated because of limited tumor samples. In addition, 12 of 14 the tumors (85.7%) were characterized by poor differentiation.
NGS Analysis of ALK IHC D5F3-Positive and FISH-Negative Cases
Of the 11 cases with ALK IHC D5F3-positive and FISH-negative results that were analyzed with NGS, eight (57.1% of the aforementioned 14 cases) were identified to have EML4-ALK rearrangement, including one case with EML4-ALK variant 1, two cases with variant 2, four cases with fusion variants 3a/b, and one case with variant 5 (see Fig. 1 and Table 3 ). The relative abundance of EML4-ALK fusion ranged from 0.9% to 46.8%. Although there were EML4-ALK fusions, the observed images were fused signals and turned out to be FISHnegative results according to the current criteria (see Fig. 1 ). Of the eight cases with EML4-ALK fusion, five had accompanying tumor protein p53 gene (TP53) mutations, one case included a phosphatase and tensin homolog gene (PTEN) R173C mutation, and two were without other gene mutation. In addition, we performed copy number variants analysis of these cases and found that two cases demonstrated copy number loss in exons 1 to 18 of the ALK gene. In addition, three patients with confirmed IHC positivity and negative FISH results did not exhibit any type of ALK fusions.
NGS Analysis of Cases with an Atypical FISH Pattern
In addition to the FISH-negative and IHC-positive patients, three patients demonstrated atypical FISH patterns. Two patients showed an isolated 5 0 side signal. Targeted NGS analysis revealed two novel ALK partner genes, BIRC6 and phosphatidylinositol binding clathrin assembly protein gene (PICALM) (Fig. 1) . Direct Sanger sequencing demonstrated that intron 10 of BIRC6 is disrupted at a point 7. 
Outcomes of Targeted Therapies
Of 14 patients with ALK IHC D5F3-positive and FISHnegative results or atypical FISH patterns, four patients received crizotinib orally at a dose of 250 mg twice daily. 
Discussion
Identification of the appropriate patient population with reliable detection methods is the key to NSCLC targeted therapies. Previous studies have indicated that Vetana-D5F3 IHC is a highly sensitive and specific method for detection of ALK status and is a viable alternative to ALK FISH. In this study, we reported a large cohort of 3128 cases screened for ALK fusions through both FISH analysis and IHC assays with Ventana-D5F3 antibody and demonstrated some negative and atypical FISH patterns accompanied with positive IHC results. The most valuable finding of this study is that patients with EML4-ALK fusion under complicated rearrangement events may demonstrate negative FISH and positive IHC results and that these patients could possibly benefit from ALK-targeted therapy. In addition, we discovered three novel ALK fusion genes with atypical FISH patterns. On the basis of these findings, combinational assay of FISH and IHC methods is highly recommended in routine pathological diagnosis, and when negative and atypical FISH patterns are accompanied by positivity in IHC, it is reasonable that corroborative testing with RT-PCR or NGS be implemented.
EML4 is the predominant fusion partner gene of ALK and both of these genes are located on short arm of chromosome 2 and separated from each other by 12.3 megabases. Most frequently, EML4-ALK is produced through chromosomal rearrangements of inv(2)(p21p23), and in this case, split patterns of 5 0 and 3 0 signals are seen in the FISH assay. 25 In addition, approximately 30% of the cases with EML4-ALK show an isolated 3 0 side signal pattern, and in this case, the 5 region of ALK is likely to be deleted during rearrangement. Usually, the broken apart and isolated red signal are considered positive FISH results; however, previous studies have demonstrated that an isolated 5 0 side signal pattern is accompanied by IHC positivity and patients with a positive IHC and traditional "negative FISH" result could also benefit from ALK inhibitor therapy. 26 In this study, there were two cases with both a fused signal and an isolated 5 0 side signal showing IHC positivity. NGS revealed a new ALK partner gene, BIRC6, and the paracentric inversion for generating this fusion gene. 11 Given the short distance (approximately 3 megabases) between two breakpoints in ALK and BIRC6, the inversion may not be revealed by breaking apart signals. In another case with an isolated 5 0 side signal pattern showing EML4-ALK fusion, the ALK downstream region is highly likely to be largely deleted and the remaining region including the ALK kinase domain (approximately 30 kilobases) is too short to be clearly observed with FISH on formalin-fixed, plasma-embedded specimens.
There were eight cases with ALK IHC D5F3-positive and FISH-negative results, demonstrating EML4-ALK rearrangement revealed by NGS. This is the first large report describing the patients carrying an EML4-ALK fusion gene with observed fused signals in FISH assay. We speculated that in such cases, the fusion of EML4 and ALK may be accompanied with some very rare events, such as simultaneous deletions of 5 0 and downstream regions and a large deletion between ALK and EML4. We performed copy number variants analysis of these eight cases and found that two demonstrated copy number loss in exons 1 to 18 of the ALK gene. Although the remaining six cases did not reveal copy number loss in ALK gene, another mechanism such as chromothripsis may contribute to the complicated rearrangement of EML4-ALK fusion gene in some very rare cases. Kodama et al. reported that chromothripsis could cause a catastrophic chromosome breakage and a small insertion of the N terminus of EML4 into the intracellular kinase domain of ALK could form a EML4-ALK fusion gene. 12 In addition, five of eight patients with EML4-ALK rearrangement and a negative FISH result demonstrated TP53 mutations. Previous studies have indicated that TP53 mutations plays a context-specific role in catastrophic DNA rearrangements in acute myeloid leukemia 27 and pediatric medulloblastoma. 28 Although there was no report of this connection in NSCLC, our results may indicate a role of TP53 mutation and DNA chromothripsis in some very rare complicated ALK rearrangement events. Four patients with negative FISH patterns demonstrated a good response to crizotinib treatment, and this indicates that IHC detection could also recognize a functional ALK pattern. This is in accordance with previous findings that patients with IHC-positive and FISH-negative ALK status show a dramatic response to crizotinib treatment. 29 We investigated mesenchymal-to-epithelial factor MET IHC, MNNG HOS Transforming gene (MET) exon 14 skipping mutation, and ROS1 fusion status in three cases with an IHCpositive/FISH-negative/NGS-negative result; however, there was no evidence demonstrating these gene alternations. In addition, Wiesner et al. have indicated that alternative transcriptional initiation of ALK could stimulate downstream oncogenic tyrosine kinase activity and patients with this novel ALK isoform may benefit from ALK inhibitors. 30 Three patients in our study with fused FISH signals demonstrated positive IHC results and NGS revealed no fusion with EML4 or other partner genes, which may be attributed to this mechanism.
In this study, we identified three novel ALK partner genes; they are BIRC6, CEBPZ, and PICALM. IHC assay with Ventana D5F3 antibody demonstrated strong cytoplasmic staining for all three cases. However, FISH analysis of BIRC6-ALK revealed a negative result and this may be largely explained by the short distance between two breakpoints in these two genes. Another fusion gene, CEBPZ-ALK, demonstrated fused signals and isolated and attenuated 3 0 red signals. An isolated 3 0 side signal pattern demonstrated FISH positivity in approximately 40% of all EML4-ALK cases and this was attributed to the 5 0 region of ALK being deleted during rearrangement. A PICALM-ALK fusion gene was also identified in an atypical FISH-negative case. However, it was hard to explain the fused signals observed in this case because PICALM was located at chromosome 11 and it was supposed to be indicated by break-apart signals. A possible mechanism for this case may be the large deletion between PICALM and ALK, as a result of which it appeared as fused signals.
Although IHC is a technically easy and routine pathological diagnostic procedure in ALK detection, there are some limitations in IHC methods. First, because IHC does not directly demonstrate ALK fusion, certain SCLCs with neuroectodermal differentiation could have positive reactions without ALK rearrangements in genomic level. 31 Second, false-negative and false-positive results of IHC testing could also happen when the procedure for using the detection system was not accurately performed. Therefore, combinational assay including the ALK FISH and IHC methods is highly recommended to accurately select the patients who could potentially benefit from targeted therapy.
In summary, we report a large cohort of screening for ALK fusions through both FISH analysis and IHC assays. In the FISH-negative and IHC-positive cases, our study demonstrated for the first time some rare genomic events in EML4-ALK rearrangement and discovered three novel ALK partner genes in these discordant cases.
In addition, some of these patients showed clinical improvement with crizotinib treatment. Therefore, combinational assay of FISH and IHC for detecting the ALK fusion should be implemented in the routine pathological diagnosis. When negative and atypical FISH patterns are accompanied by positivity in IHC, it is reasonable that corroborative testing with RT-PCR or NGS be conducted and these patients may benefit from ALK-targeted therapy.
